JOP20190255A1 - صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها - Google Patents
صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامهاInfo
- Publication number
- JOP20190255A1 JOP20190255A1 JOP/2019/0255A JOP20190255A JOP20190255A1 JO P20190255 A1 JOP20190255 A1 JO P20190255A1 JO P20190255 A JOP20190255 A JO P20190255A JO P20190255 A1 JOP20190255 A1 JO P20190255A1
- Authority
- JO
- Jordan
- Prior art keywords
- formulations
- methods
- human anti
- same
- rankl antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
يتعلق الاختراع الحالي بالكشف عن صيغ صيدلية مائية تشتمل على دينوسوماب أو جسم مضاد أحادي النسيلة مضاد لـ RANKL بشري آخر أو جزء منه، ولها خصائص رقم هيدروجيني (pH)، أنظمة محاليل منظِّمة، ومثبطات تراكم أحماض أمينية. ويتعلق الاختراع أيضًا بالكشف عن شكل الصيغة لاستخدامها، على سبيل المثال في قنينة تُستخدم مرةً واحدة، أو محقنة تُستخدم مرةً واحدة، أو حاوية زجاجية، كما يتعلق بطرق لاستخدام الصيغ والمنتجات للوقاية من أو علاج أمراض، وبأطقم ذات صلة. الشكل 1
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762492056P | 2017-04-28 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20190255A1 true JOP20190255A1 (ar) | 2019-10-27 |
Family
ID=62165668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0255A JOP20190255A1 (ar) | 2017-04-28 | 2017-06-16 | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
Country Status (31)
Country | Link |
---|---|
US (2) | US11192952B2 (ar) |
EP (2) | EP4190355A1 (ar) |
JP (3) | JP7190822B2 (ar) |
KR (1) | KR20190140464A (ar) |
CN (1) | CN110621342A (ar) |
AR (1) | AR111497A1 (ar) |
AU (1) | AU2018260750A1 (ar) |
BR (1) | BR112019022188A2 (ar) |
CA (1) | CA3054165A1 (ar) |
CL (3) | CL2019003032A1 (ar) |
CO (1) | CO2019011463A2 (ar) |
CR (1) | CR20190538A (ar) |
DK (1) | DK3615066T3 (ar) |
EA (1) | EA201992570A1 (ar) |
FI (1) | FI3615066T3 (ar) |
HR (1) | HRP20240167T1 (ar) |
IL (2) | IL293127B1 (ar) |
JO (1) | JOP20190255A1 (ar) |
LT (1) | LT3615066T (ar) |
MA (1) | MA48462A (ar) |
MY (1) | MY202479A (ar) |
PE (1) | PE20200343A1 (ar) |
PH (1) | PH12019502444A1 (ar) |
PL (1) | PL3615066T3 (ar) |
PT (1) | PT3615066T (ar) |
RS (1) | RS65299B1 (ar) |
SG (1) | SG11201909998TA (ar) |
SI (1) | SI3615066T1 (ar) |
TN (2) | TN2021000055A1 (ar) |
UY (1) | UY37707A (ar) |
WO (1) | WO2018200918A1 (ar) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113365658A (zh) * | 2018-11-16 | 2021-09-07 | 三星Bioepis股份有限公司 | 包含蛋白质的稳定的液体组合物 |
CN109374779A (zh) * | 2018-12-17 | 2019-02-22 | 杭州奕安济世生物药业有限公司 | 一种蔗糖含量的快速检测方法 |
CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
CN111704670B (zh) * | 2020-08-18 | 2020-11-03 | 迈威(上海)生物科技股份有限公司 | 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法 |
EP4339207A1 (en) * | 2021-05-12 | 2024-03-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof |
AU2022325870A1 (en) | 2021-08-12 | 2024-02-08 | Amgen Inc. | Antibody formulations |
WO2023092177A1 (en) * | 2021-11-23 | 2023-06-01 | Adalta Limited | Rank-l binding molecules |
WO2023179791A1 (en) * | 2022-03-24 | 2023-09-28 | Angitia Biomedicines Limited | Treatment of musculoskeletal disorders |
WO2024064878A1 (en) | 2022-09-23 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of melanoma |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4212470B2 (ja) | 2001-06-26 | 2009-01-21 | アムジェン フレモント インク. | Opglへの抗体 |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
MX2009006594A (es) * | 2006-12-21 | 2009-08-12 | Amgen Inc | Formulaciones de ph regulado y estables que contienen polipeptidos. |
US7951368B2 (en) * | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
BRPI0908361A2 (pt) | 2008-02-07 | 2015-04-07 | Amgen Inc | Seringas previamente cheias contendo composição e métodos de preparação das mesmas e de estabilização de agente de ligação específico em composição. |
AR073072A1 (es) | 2008-08-19 | 2010-10-13 | Regeneron Pharma | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
CN102946858B (zh) | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | 含有免疫球蛋白Fc的多肽的液体制剂 |
EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
JP2014510152A (ja) * | 2011-04-07 | 2014-04-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 粘度が低減された処方物 |
CA2951856A1 (en) | 2011-10-28 | 2013-05-02 | Integritybio Inc. | Protein formulations containing amino acids |
TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
CN103965357B (zh) | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
US20150274819A1 (en) | 2014-03-03 | 2015-10-01 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
EP3139960B1 (en) | 2014-05-07 | 2024-01-17 | Takeda Pharmaceutical Company Limited | Liquid formulation comprising gm-csf neutralizing compound |
-
2017
- 2017-06-16 JO JOP/2019/0255A patent/JOP20190255A1/ar unknown
-
2018
- 2018-04-27 PT PT187246905T patent/PT3615066T/pt unknown
- 2018-04-27 PL PL18724690.5T patent/PL3615066T3/pl unknown
- 2018-04-27 US US16/608,375 patent/US11192952B2/en active Active
- 2018-04-27 CA CA3054165A patent/CA3054165A1/en not_active Abandoned
- 2018-04-27 EP EP22206709.2A patent/EP4190355A1/en active Pending
- 2018-04-27 EP EP18724690.5A patent/EP3615066B1/en active Active
- 2018-04-27 JP JP2018086261A patent/JP7190822B2/ja active Active
- 2018-04-27 SG SG11201909998T patent/SG11201909998TA/en unknown
- 2018-04-27 AR ARP180101105A patent/AR111497A1/es unknown
- 2018-04-27 LT LTEPPCT/US2018/029728T patent/LT3615066T/lt unknown
- 2018-04-27 BR BR112019022188-3A patent/BR112019022188A2/pt unknown
- 2018-04-27 CN CN201880028012.1A patent/CN110621342A/zh active Pending
- 2018-04-27 KR KR1020197034225A patent/KR20190140464A/ko active IP Right Grant
- 2018-04-27 MA MA048462A patent/MA48462A/fr unknown
- 2018-04-27 AU AU2018260750A patent/AU2018260750A1/en active Pending
- 2018-04-27 PE PE2019002120A patent/PE20200343A1/es unknown
- 2018-04-27 EA EA201992570A patent/EA201992570A1/ru unknown
- 2018-04-27 TN TNP/2021/000055A patent/TN2021000055A1/en unknown
- 2018-04-27 IL IL293127A patent/IL293127B1/en unknown
- 2018-04-27 RS RS20240313A patent/RS65299B1/sr unknown
- 2018-04-27 WO PCT/US2018/029728 patent/WO2018200918A1/en active Application Filing
- 2018-04-27 UY UY0001037707A patent/UY37707A/es unknown
- 2018-04-27 DK DK18724690.5T patent/DK3615066T3/da active
- 2018-04-27 HR HRP20240167TT patent/HRP20240167T1/hr unknown
- 2018-04-27 FI FIEP18724690.5T patent/FI3615066T3/fi active
- 2018-04-27 TN TNP/2019/000297A patent/TN2019000297A1/en unknown
- 2018-04-27 SI SI201831067T patent/SI3615066T1/sl unknown
- 2018-04-27 MY MYPI2019006326A patent/MY202479A/en unknown
- 2018-04-27 CR CR20190538A patent/CR20190538A/es unknown
-
2019
- 2019-08-14 IL IL268704A patent/IL268704B/en unknown
- 2019-10-16 CO CO2019011463A patent/CO2019011463A2/es unknown
- 2019-10-23 CL CL2019003032A patent/CL2019003032A1/es unknown
- 2019-10-28 PH PH12019502444A patent/PH12019502444A1/en unknown
-
2020
- 2020-07-31 CL CL2020002012A patent/CL2020002012A1/es unknown
-
2021
- 2021-11-18 US US17/529,794 patent/US11873343B2/en active Active
-
2022
- 2022-01-14 JP JP2022004150A patent/JP7356525B2/ja active Active
-
2023
- 2023-08-10 JP JP2023130715A patent/JP2023166396A/ja active Pending
- 2023-08-24 CL CL2023002505A patent/CL2023002505A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502444A1 (en) | Formulations of human anti-rankl antibodies, and methods of using the same | |
CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
PH12019502123A1 (en) | Stable antibody formulation | |
MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
BR112015022210A2 (pt) | formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica. | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
PH12019501979A1 (en) | Anti-rsv monoclonal antibody formulation | |
MX2020008219A (es) | Formulacion farmaceutica de ph bajo. | |
PH12014502429A1 (en) | Stabilized formulations containing anti-dll4 antibodies | |
WO2018048941A3 (en) | USE OF BINDERS OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCTS TO INCREASE THE ACTION TIME OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN BIOLOGICAL TISSUE | |
MX2021009851A (es) | Formulacion de anticuerpos terapeuticos. | |
AR117607A1 (es) | Formulaciones de anticuerpo líquidas de alta concentración | |
MX2021007047A (es) | Formulaciones de anticuerpos. | |
MX2018005226A (es) | Formulaciones de anticuerpo anti-factor d. | |
CR20200552A (es) | Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe | |
CL2022001243A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas divisional solicitud no. 201903032 |